Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Operating Leases (2020 - 2025)

Revolution Medicines has reported Operating Leases over the past 6 years, most recently at $142.2 million for Q4 2025.

  • Quarterly results put Operating Leases at $142.2 million for Q4 2025, up 15.66% from a year ago — trailing twelve months through Dec 2025 was $142.2 million (up 15.66% YoY), and the annual figure for FY2025 was $142.2 million, up 15.66%.
  • Operating Leases for Q4 2025 was $142.2 million at Revolution Medicines, roughly flat from $142.1 million in the prior quarter.
  • Over the last five years, Operating Leases for RVMD hit a ceiling of $142.2 million in Q4 2025 and a floor of $26.8 million in Q3 2021.
  • Median Operating Leases over the past 5 years was $60.0 million (2021), compared with a mean of $75.8 million.
  • Peak annual rise in Operating Leases hit 282.2% in 2021, while the deepest fall reached 9.58% in 2021.
  • Revolution Medicines' Operating Leases stood at $60.4 million in 2021, then decreased by 4.94% to $57.4 million in 2022, then soared by 40.3% to $80.6 million in 2023, then soared by 52.62% to $123.0 million in 2024, then increased by 15.66% to $142.2 million in 2025.
  • The last three reported values for Operating Leases were $142.2 million (Q4 2025), $142.1 million (Q3 2025), and $119.7 million (Q2 2025) per Business Quant data.